Polypill and Global Cardiovascular Health Strategies

Seminars in Thoracic and Cardiovascular Surgery

Volumn 23, Issue 1, 2011, Pages 24-29

  Sanz, Ginés ^a   Fuster, Valentin ^a,b  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular prevention; Polypill; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ASPIRIN PLUS ATENOLOL PLUS ATORVASTATIN PLUS LOSARTAN; ASPIRIN PLUS ATENOLOL PLUS HYDROCHLOROTHIAZIDE PLUS RAMIPRIL PLUS SIMVASTATIN; ASPIRIN PLUS ATENOLOL PLUS LISINOPRIL PLUS SIMVASTATIN; ASPIRIN PLUS ATORVASTATIN PLUS METOPROLOL SUCCINATE PLUS RAMIPRIL; ASPIRIN PLUS ATORVASTATIN PLUS RAMIPRIL; ASPIRIN PLUS ATORVASTATIN PLUS RAMIPRIL PLUS METOPROLOL; ASPIRIN PLUS HYDROCHLOROTHIAZIDE PLUS LISINOPRIL PLUS SIMVASTATIN; ASPIRIN PLUS LISINOPRIL PLUS LOVASTATIN; ASPIRIN PLUS RAMIPRIL PLUS SIMVASTATIN; ATENOLOL; ATORVASTATIN PLUS RAMIPRIL; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POLYCAP; POLYPILL; RED HEART PILL; RED HEART PILL 2B; SIMVASTATIN; TRINOMIA; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR DISEASE; DRUG COST; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; LIFESTYLE MODIFICATION; MORTALITY; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY PREVENTION; SECONDARY PREVENTION; UNSPECIFIED SIDE EFFECT;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DRUG COMBINATIONS; DRUG COSTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MEDICATION ADHERENCE; PREVENTIVE HEALTH SERVICES; RISK ASSESSMENT; RISK FACTORS; WORLD HEALTH;

EID: 79960907791     PISSN: 10430679     EISSN: 15329488     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2011.05.005     Document Type: Article

References (41)

1. WHO report: Preventing chronic disease, Accessed March 2011. http://www.who.int/chp/chronic_disease_report.
2. European Health Heart Charter, Accessed September 2010. http://www.heartcharter.eu/.
3. Reddy K.S. Cardiovascular diseases in the developing countries: Dimensions, determinants, dynamics and directions for public health action. Public Health Nutr 2002, 5:231-237.
4. Lopez A.D., Mathers C.D., Ezzati M., et al. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2006, 367:1747-1757.
5. Daar A.S., Singer P.A., Persad D.L., et al. Grand challenges in chronic non-communicable diseases. Nature 2007, 450:494-496.
6. Yusuf S., Hawken S., Ounpuu S., et al. INTERHEART study investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study)-Case-control study. Lancet 2004, 364:937-952.
7. Cooney M.T., Dudina A., Whincup P., et al. Re-evaluating the Rose approach: Comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil 2009, 16:541-549.
8. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Executive summary: Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 2010, 121:948-954.
9. Wong M.D., Shapiro W.J., Ettner S.l., et al. Contribution of major diseases to disparities in mortality. N Engl J Med 2002, 347:1585-1589.
10. Mackenbach J.P., Stirbu I., Roskam A.J., et al. Socioeconomic inequalities in health in 22 European countries. N Engl J Med 2008, 358:2468-2481.
11. Fuster V., Kelly B., Vedanthan R. Promoting global cardiovascular health: Moving forward. Circulation 2011, 123:1671-1678.
12. Kotseva K., Wood D., De Backer G., et al. Cardiovascular prevention guidelines in daily practice: A comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373:929-940.
13. Muntner P., Mann D., Wildman R.P., et al. Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects. Am Heart J 2011, 161:719-725.
14. Mendis S., Abegunde D., Yusuf S., et al. WHO study on prevention of recurrences of myocardial infarction and stroke (WHO-PREMISE). Bull World Health Organ 2005, 83:820-828.
15. Price, availability and affordability: An international comparison of chronic disease medicines December 2005, World Health Organization, World Health Organization, Cairo, Egypt.
16. Mendis S., Fukino K., Cameron A., et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 2007, 85:279-288.
17. Bosworth H.B. Medication treatment adherence, in Bosworth H, Oddone E, Weinberger M (eds): Patient Treatment Adherence. Mahwah, New Jersey, Lawrence Erlbaum Associates 2006, 147-194.
18. Cutler D.M., Everett W. Thinking outside the pillbox: Medication adherence as a priority for health care reform. N Engl J Med 2010, 362:1553-1555.
19. Jansà M., Hernández C., Vidal M., et al. Multidimensional analysis of treatment adherence in patients with multiple chronic conditions: A cross-sectional study in a tertiary hospital. Patient Educ Couns 2010, 81:161-168.
20. Bramlage P., Messer C., Bitterlich N., et al. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart 2010, 96:604-609.
21. Danchin N., Cambou J.P., Hanania G., et al. Impact of combined secondary prevention therapy after myocardial infarction: Data from a nationwide French registry. Am Heart J 2005, 150:1147-1153.
22. Lonn E., Yusuf S. Polypill: The evidence and the promise. Curr Opin Lipidol 2009, 20:453-459.
23. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419.
24. Wald N.J., Wald D.S. The polypill concept. Heart 2010, 96:1-4.
25. Wald N.J., Wald D.S. The polypill concept. Postgrad Med J 2010, 86:257-260.
26. Wald D.S., Wald N.J. The polypill in the primary prevention of cardiovascular disease. Fundam Clin Pharmacol 2010, 24:29-35.
27. Sleight P., Pouleur H., Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J 2006, 27:1651-1656.
28. Reddy S. The preventive polypill: Much promise, insufficient evidence. N Engl J Med 2007, 356:212.
29. Teo K.K., Liang L.Y. Polypill: Lights and shadows. Curr Hypertens Rep 2010, 12:276-281.
30. Yusuf S., Pais P., Afzal R., et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): A phase II, double-blind, randomised trial. Lancet 2009, 373:1341-1351.
31. Graziano T.A., Opie L.H., Weinstein M.C. Cardiovascular disease prevention with a multidrug regimen in the developing world: A cost-effectiveness analysis. Lancet 2006, 368:679-686.
32. Malekzadeh F., Marshall T., Pourshams A., et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ("polypill") on cardiovascular risk factors. Int J Clin Pract 2010, 64:1220-1227.
33. Polypill holds promise for people with chronic disease. Bull World Health Organ 2005, 83:885-887. World Health Organization.
34. Kaplan W., Laing R. Priority medicines for Europe and the world: World Heart Organization Accessed June 9, 2011. http://whqlibdoc.who.int/hq/2004/WHO_EDM_PAR_2004.7.pdf.
35. Second WHO and Wellcome Trust Workshop in Secondary Prevention of Cardiovascular Disease in Low & Middle Income Countries: Building the evidence base on secondary prevention of CVD. London, June 6-8, 2007.
36. Bangalore S., Kamalakkannan G., Parkar S., et al. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med 2007, 120:713-719.
37. Fuster V., Sanz G. Compuestos a dosis fijas en la prevención secundaria de la cardiopatía isquémica. Rev Esp Cardiol 2011, (suppl 2):64. in press.
38. Sanz G., Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: Rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med 2009, 6:101-110.
39. Guglietta A., Guerrero M. Issues to consider in the pharmaceutical development of a cardiovascular polypill. Nat Clin Pract Cardiovasc Med 2009, 6:112-119.
40. Patel A., Shah T., Shah G., et al. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): A five-arm phase I crossover trial in healthy volunteers. Am J Cardiovasc Drugs 2010, 10:95-103.
41. Forslund L. Reflections on the regulation of the Polypill. Nat Clin Pract Cardiovasc Med 2009, 6:94-95.